Drug details

Simponi Aria (golimumab for infusion)

type of DMARDs, TNF Inhibitors, Monoclonal Antibodies, Antipsoriatics, Systemic, Inflammatory Bowel Disease Agents

Simponi Aria (golimumab) for infusion is a monoclonal antibody used in combination with methotrexate to treat adult patients with moderately to severely active rheumatoid arthritis.

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • loss of appetite,
  • dark urine,
  • vomiting,
  • fever,
  • shortness of breath,
  • chills,
  • stomach pain,
  • cough,
  • unusual tiredness,
  • chest pain, and
  • unusual sweating,
  • vision changes,
  • persistent sore throat,
  • muscle or joint pain,
  • easy bruising or bleeding,
  • severe dizziness,
  • seizures
  • persistent nausea,
  • unsteadiness,
  • swelling of the ankles or feet,
  • sudden weight gain,
  • yellowing of the eyes or skin (jaundice)
  • numbness or tingling of the hands or feet,
  • unexplained muscle weakness,
  • butterfly-shaped rash on the nose and cheeks,
The following drugs are related to Simponi Aria, either as a replacement or used together:
  • Abrilada (adalimumab-afzb injection, for subcutaneous use)
  • Clanza CR (aceclofenac tablet, film coated)
  • Humira (adalimumab injection solution for subcutaneous administration)
  • Idacio (adalimumab-aacf injection)
  • Yusimry (adalimumab-aqvh injection)
  • Imraldi (adalimumab-xxxx injection, for subcutaneous use)
  • Azasan (azathioprine)
  • Olumiant (baricitinib tablets)
  • Celebrex (celecoxib)
  • Colocort (hydrocortisone rectal suspension)
  • Cortaren (dexamethasone sodium phosphate injection)
  • Duobrii (halobetasol propionate and tazarotene lotion)
  • Eticovo (etanercept injection)
  • Simponi Injection (golimumab injection)
  • Inflectra (infliximab-dyyb intravenous injection)
  • Kevzara (sarilumab injection, for subcutaneous use)
  • Meloxicam Tablets (meloxicam)
  • Morphabond (morphine sulfate extended-release tablets)
  • Rinvoq (upadacitinib extended-release tablets)
  • Skyrizi (risankizumab-rzaa injection)
  • Tofidence (tocilizumab-bavi injection)